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ABSTRACT
Objective: To describe patient characteristics, treatment patterns and healthcare utilization
(HCU) of non-active users of maintenance asthma medications in the United Kingdom.
Methods: Retrospective, cohort analysis of patients with asthma, aged  6 years who were
non-active users of maintenance therapy (no prescription for inhaled corticosteroids (ICS),
combined ICS/long-acting beta agonists (ICS/LABA) or ‘other’ bronchodilatory therapies in
last 12months) were identified in the Clinical Practice Research Datalink (2012–2015) and
followed-up for 2 years after a new prescription for an asthma maintenance medication
(index date). Patient characteristics, most common maintenance treatment sequences and
HCU were described.
Results: 55,293 patients were identified (ICS: 46,297, ICS/LABA: 8,367; Other: 629). Mean age
was 37 years and 56% were female. During follow-up, the most common treatment sequences
across groups implied intermittent use, comprising periods of maintenance therapy inter-
spersed with maintenance-free periods. During year 1 and year 2 of follow-up, the proportion
of patients prescribed OCS was 19% and 13%, prescribed  4 short-acting bronchodilators
(SABD) was 24% and 19%, having  3 asthma-related primary care consultations/year was
59% and 36% and experiencing  1 exacerbation/year was 15% and 11%, respectively.
Conclusions: In previously non-active users of asthma maintenance medication subsequently
commenced on maintenance therapy, intermittent use was common during the 2-year follow-
up despite the potential need for regular use as evidenced by patient HCU and SABD usage
patterns. This highlights the need for regular patient assessment and education on medication
adherence to ensure appropriateness of prescribing to maintain asthma control.
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Introduction
Asthma is one of the most common chronic, non-com-
municable diseases worldwide and is responsible for a
substantial social and economic burden, causing lost
days at work and school, and impaired quality of life
through limitations in daily activities and sleep distur-
bances (1–3). The main goals of asthma treatment are to
achieve good symptom control whilst minimizing the
future risk of exacerbations, fixed airflow obstruction and
treatment side-effects (2,4–6). Successful asthma manage-
ment requires a comprehensive, holistic approach in
selecting the most appropriate asthma medication and
inhaler for a given patient and initiating a regimen of
treatment that will ensure appropriate medication-taking
behaviors over time. Pharmacological therapies are only
one aspect of optimal care, and treatment plans should
address modifiable risk factors, ensure high-quality com-
munication between healthcare professionals and
CONTACT Daniel C. Gibbons daniel.c.gibbons@gsk.com Data Methods & Analytics, Uxbridge, GSK, UK.
Supplemental data for this article is available online at at www.tandfonline.com/ijas.
 2020 GlaxoSmithKline plc. Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
JOURNAL OF ASTHMA
https://doi.org/10.1080/02770903.2020.1728767
patients, matching the patient with the most suitable
inhaler, regular follow-up, and empower patient self-
management through education and personalized written
action plans (1,2,4–6).
Asthma guidelines recommend a stepwise approach to
pharmacological treatment, titrating changes in therapy –
be it changes in dose regimen, medication or delivery
device - to achieve adequate control of symptoms (2,4,5).
Inhaled corticosteroids (ICS) are considered the most
effective anti-inflammatory treatment for all severities of
persistent asthma, and early initiation of ICS after asthma
diagnosis is associated with long-term benefits in lung
function and asthma control; oral therapies such as leuko-
triene receptor antagonists (LTRAs) and xanthine deriva-
tives (e.g. theophylline) are alternatives to ICS but do not
have as marked an effect on inflammation (2,4–7).
For patients who remain poorly controlled on ICS,
the addition of a long-acting beta2-agonist (LABA) is
the preferred next step (2,8); should patients remain
uncontrolled, therapy can be further intensified through
increasing medication dosage, addition of another con-
troller medication and, in refractory cases, addition of
systemic therapies such as oral corticosteroids (OCS) or
biologics (e.g. anti-IL5, anti-IgE) (2). Ongoing evaluation
of pharmacological treatment efficacy is based on the
review/assessment of symptom control, risk factors,
comorbidities, treatment side-effects, and patient adher-
ence to and satisfaction with treatment (1,2,9).
There is limited understanding of the long-term
real-world maintenance treatment patterns in the
broad asthma population. Most data, collected
through clinical trials and observational studies, have
typically evaluated outcomes associated with a specific
step-up or step-down in therapy rather than describ-
ing changes in prescribed asthma therapy over time
(10–14). This study aims to address this knowledge
gap through describing the patient characteristics,
healthcare utilization (HCU) and in particular treat-
ment patterns, of non-active users of maintenance
asthma medications among the primary care popula-
tion of asthmatics in the United Kingdom (UK), in a
large, nationally representative, primary care dataset.
Methods
Data source and patients
This retrospective, cohort study used data extracted
from the Clinical Practice Research Datalink (CPRD)
(period between 1 January 2012 and 31 December
2017) (GSK study 209142). CPRD contains anony-
mized, longitudinal patient-level data from the elec-
tronic medical records of a representative sample of
the UK primary care practices and includes data on
primary care medical consultations, prescriptions,
results of investigations ordered by primary care, and
referrals to specialists (15,16).
The source population for this study was defined as
individuals with a diagnosis of asthma who had not
received maintenance therapy (ICS/LABA, ICS or
‘other’ indicated therapies) for a period of at least
12months between January 1 2012 and December 31
2015 and, as such, were deemed ‘non-active’ users of
maintenance therapy. Members of this ‘non-active’
population who were subsequently prescribed an
asthma maintenance therapy were identified using a
new user design and were the analysis population for
this study; the date of this prescription was defined as
the index date and the 12months immediately prior
to this index prescription as the baseline period.
Eligible patients were  6 years of age at the index
date with an asthma diagnosis on or before the index
date and had not been prescribed a maintenance medi-
cation for asthma in the 12months immediately pre-
ceding their index maintenance prescription. All
patients had at least 3 years of continuous data (1 year
prior to and 2 years post-index date) within the study
period. Patients diagnosed with one or more of chronic
obstructive pulmonary disease, an interstitial lung dis-
ease, cystic fibrosis or lung cancer was excluded.
In the 2-year follow-up period from the index date,
data on treatment patterns, HCU and the occurrence of
asthma exacerbations (as defined below) were assessed.
The Independent Scientific Advisory Committee
approved the use of CPRD data for this study (ISAC
protocol 19_128R) and the protocol complied with all
applicable laws regarding subject privacy. As the study
involved no direct subject contact or primary collec-
tion of individual human subject data, and all data
were anonymized, patient informed consent, ethics
committee or IRB approval were not required.
Study variables
Patient characteristics
Patient characteristics of age, gender and ethnicity (at
index date), comorbidities, history of atopy and diag-
nosis of exercise-induced bronchoconstriction (during
baseline year), and previous asthma maintenance
medication history (prior to the 1-year baseline
period) were recorded.
Asthma treatment
For patients in each of the index therapy categories,
prescribed asthma therapies (at the level of treatment
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class – e.g. ICS, ICS/LABA) over the 2-year observa-
tion period were determined. Changes in prescribed
compounds were classified in terms of whether they
were an augmentation (an addition of another therapy
from a different class), a therapy switch (either
within- or between-class) or a discontinuation of ther-
apy. Discontinuation was defined as a gap of 
61 days between the projected end date of one pre-
scription (defined as the date of issueþ days supplied)
and the date of the next prescription issued to the
patient (should one exist), with the date of discontinu-
ation defined as the end date of the prescription
immediately prior to the discontinuation.
Type of inhaler device prescribed was described at
index, as well as during the first and second year of
follow-up among those prescribed further inhalers.
Healthcare utilization (HCU)
All primary care consultations with a non-administrative
healthcare professional together with those that were
specifically asthma-related (i.e. an asthma Read code
recorded against it) were identified. Hospitalizations, as
recorded in primary care records, were identified for all-
cause and asthma-related admissions. Short-acting bron-
chodilator (SABD) use was described as the number of
SABD devices prescribed by primary care.
Asthma exacerbations were defined as an asthma-
related emergency department (ED) visit/hospital
admission or requirement for OCS treatment (17).
Additional exacerbations were required to be at least
7 days after the end of an OCS course or discharge
date from ED/hospital to be considered a separ-
ate event.
In addition to HCU assessments, the number of
patients having a RCP3Q assessment was documented
for year 1 and year 2 of follow-up. The RCP3Q is a
component of the asthma annual review within the
Quality and Outcome Framework that was added in
2012, and is a pay for performance scheme for pri-
mary care practices in the UK (18,19). The three ques-
tions in RCP3Q relate to the impact of asthma on
sleep, symptoms and usual activities; all 3 questions
should be asked on the same date to count as a valid
RCP3Q assessment. Valid RCP3Q assessments were
identified using the methods stipulated in V38 of the
QOF Business Rules (20) or recording of a single
Read code denoting administration of the RCP3Q.
Statistical analysis
Descriptive data were described for all patients and by
index medication class as either mean (standard
deviation [SD]) or median (interquartile range [IQR])
for continuous variables and the count and proportion
of patients for categorical and ordinal variables.
Prescriptions for maintenance asthma medications
subsequent to the index date were used to construct
treatment sequences. The five most common mainten-
ance medication class sequences for each index main-
tenance therapy group (ICS/LABA, ICS, other) up to
the end of the 2-year follow-up period were reported,
including the mean (SD) and median (IQR) time
between changes in sequences. Within index groups,
the proportion of patients (%) following each of the
most common treatment patterns was calculated using
the total population (i.e. total number of patients
across all index therapies) as the denominator in
order to report the commonality of a particular treat-
ment pattern within this cohort of patients. Where
there was insufficient information to determine the
duration of MDI prescription length, data were
imputed using an algorithm based on modal daily
dose and quantity supplied for a particular product
code (21). Analysis of time to first therapy change was
analyzed using Kaplan-Meier estimates of the survival
function. The failure event was defined as the first
occurrence of one of, discontinuation, augmentation,
between-class switch or within-class switch (as defined
above). Censoring occurred after two years of post-
index follow-up; this was the upper limit of observa-
tion time, precluding further assessment of events in
those yet to experience a change in treatment.
Results
Study population
A total of 55 293 patients fulfilled the study criteria
and were included in the analysis (Figure 1), the
majority of whom were prescribed ICS as asthma
maintenance medication at the index date (n¼ 46 297,
84%) (Table 1). Of the 629 patients who were pre-
scribed other medications, most were prescribed
LTRA (n¼ 610). Whilst all patients had not received
an asthma maintenance treatment in the baseline year,
approximately 70% had previously been prescribed a
maintenance therapy (Table 1; Table S1, supplemen-
tary material).
For the total population, the mean age was 37 years,
56% were female. Compared with the other groups,
patients in the ICS/LABA group were older (mean age
43 years) and, consistent with this, had a higher
reported incidence of cardiovascular disease, bron-
chitis/bronchopneumonia, and metabolic disorders
(Table 1).
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Asthma treatment patterns during the 2-year
follow up period
Across groups, the most common treatment sequence
following index therapy was discontinuation of main-
tenance treatment with no further prescriptions
recorded up to the end of the 2-year observation
period (Figure 2; Table 2). Other common treatment
sequences generally showed patterns of intermittent
use, comprising periods of maintenance therapy inter-
spersed with ‘no’ therapy. The proportion of individu-
als following a given treatment sequence by age group
and by no known previous maintenance therapy was
calculated for the most common sequences in each
index therapy class (see Table S2 and Table S3,
respectively, supplementary material). The distribution
of age and prior exposure to maintenance therapy
within the most common sequences generally reflected
that of the relevant index class. The time to first treat-
ment change was later in the ICS group (Figure 3;
Table 2).
Treatments prescribed during year 1 and year 2
post-index are summarized in Table 3 and Table S4
(supplementary material). In the total population, 19%
of patients in year 1 and 13% in year 2 were pre-
scribed OCS, mostly for intermittent use, and the pro-
portion was higher in the ICS/LABA (24% and 18%,
Table 1. Baseline demographic and clinical characteristics.
Total population
Index asthma maintenance medication group
ICS ICS/LABA Otherb
Patients, n 55,293 46,297 8,367 629
Age (years)
Mean (SD) 37.0 (19.7) 35.9 (19.7) 43.3 (18.7) 33.2 (20.8)
Age group, n (%)
6-11 years 5,684 (10.3) 5,406 (11.7) 161 (1.9) 117 (18.6)
12-17 years 6,245 (11.3) 5,594 (12.1) 569 (6.8) 82 (13.0)
 18 years 43,364 (78.4) 35,297 (76.2) 7,637 (91.3) 430 (68.4)
Female, n (%) 30,923 (55.9) 25,652 (55.4) 4,914 (58.7) 357 (56.8)
Maintenance therapy before 12 month baseline perioda
No history, n (%) 16,691 (30.2) 14,679 (31.7) 1752 (20.9) 260 (41.3)
Median length of baseline history, years 9.7 9.6 10.3 9.0
URTI or LRTI in last 12 months 10,579 (19.1) 8,672 (18.7) 1,750 (20.9) 157 (25.0)
Atopy history
Positive history of atopy in last 12 months 3,535 (6.4) 2,996 (6.5) 463 (5.5) 76 (12.1)
Positive history of atopy at any time pre-index 30,870 (55.8) 25,955 (56.1) 4,491 (53.7) 424 (67.4)
Comorbidities, n (%)
Atherosclerotic, cardiac disease and circulatory disorders 4,932 (8.9) 3,870 (8.4) 1,001 (12.0) 61 (9.7)
Bronchitis and bronchopneumonia 4,731 (8.6) 3,736 (8.1) 942 (11.3) 53 (8.4)
Metabolic disorders 2,886 (5.2) 2,252 (4.9) 598 (7.1) 36 (5.7)
Psychological disease 2,326 (4.2) 1,905 (4.1) 394 (4.7) 27 (4.3)
Neurologic disorders 1,589 (2.9) 1,287 (2.8) 283 (3.4) 19 (3.0)
Exercise-induced bronchoconstriction 689 (1.3) 588 (1.3) 87 (1.0) 14 (2.2)
GORD or peptic ulceration 646 (1.2) 512 (1.1) 122 (1.5) 12 (1.9)
Immunologic and hematologic disease 466 (0.8) 349 (0.8) 105 (1.3) 12 (1.9)
Connective tissue disease 309 (0.6) 230 (0.5) 74 (0.9) 5 (0.8)
Vocal cord dysfunction 0 0 0 0
Nasal polyps 107 (0.2) 81 (0.2) 19 (0.2) 6 (1.0)
URTI: upper respiratory tract infection; LRTI: lower respiratory tract infection; GORD: Gastroesophageal reflux disease; ICS: inhaled corticosteroid; ICS/LABA:
inhaled corticosteroid/long-acting beta2-agonist.
aIn known pre-baseline history. Breakdown in length of known pre-baseline history given in supplementary material (Table S1); bIncluded leukotriene
receptor antagonists (LTRA) and methylxanthines.
Figure 1. Consort diagram.
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Figure 2. Five most common treatment sequences by index asthma maintenance medication group.
Proportions were calculated using the total number of patients across all index therapies as the denominator (n ¼ 55,293); dura-
tions above each arrow denote the mean time spent in a given treatment class by patients with that treatment sequence; total
sequence durations may not sum to the same value due to rounding and leap years.
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
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respectively) than the ICS (18% and 12%) and Other
(21% and 12%) groups. Approximately a quarter of
patients were prescribed at least four SABD inhalers
during the first year of follow-up (Figure 4).
During year 1 and 2 of follow up, most patients
remained on the same device with respect to their
maintenance therapy (Table S5, supplemen-
tary material).
Healthcare utilization
Over the 2-year follow-up period over 90% patients
across groups had three or more primary care consul-
tations per year (all-cause) (Table S6, supplementary
material). Asthma-related consultations were also
prevalent with 59% and 36% of patients requiring  3
visits during year 1 and year 2, respectively
(Supplementary Figure S1a). During year 1, the mean
(SD) exacerbation rate was 0.19 (0.5), notably higher
for patients in the ICS/LABA group (0.27 (0.61) com-
pared with the ICS (0.18 (0.48)) and Other (0.16
(0.45)) groups and a similar pattern was observed for
the proportion of patients experiencing at least one
exacerbation in that year (ICS: 14%; ICS/LABA: 20%;
Other: 13%; Figure S1b, supplementary material).
There was an attrition in exacerbations in year 2. In
general hospitalizations, as recorded in primary care,
were low across groups.
During year 1 post-index, 54% of patients had a
valid RCPQ3 assessment i.e. were asked all three
Table 2. Summary of time to first medication change and therapy change event by index treatment class.
Index medication class
All patients ICS ICS / LABA Otherb
Time to first therapy change (days) Mean 126.95 132.40 99.72 88.41
SD 150.36 149.12 153.69 152.23
95% CI Lower bound 125.70 131.04 96.42 76.50
Upper bound 128.21 133.76 103.01 100.33
Median 86 100 30 28
IQR 25th centile 50 50 28 28
75th centile 120 128 88 59
Therapy change event typea Total events n 55,293 46,297 8,367 629
% 100% 100% 100% 100%
Between-class switch n 3,844 3,565 241 38
% 7.0% 7.7% 2.9% 6.0%
Within-class switch n 2,052 1,526 509 17
% 3.7% 3.3% 6.1% 2.7%
Augmentation n 944 468 383 93
% 1.7% 1.0% 4.6% 14.8%
Discontinuation n 48,453 40,738 7,234 481
% 87.6% 88.0% 86.5% 76.5%
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist.
aNB: Therapy change from ICS to combined ICS/LABA was considered a between-class switch; therapy change from ICS to an ICS plus a LABA (not com-
bined) was considered an augmentation; bIncluded leukotriene receptor antagonists (LTRA) and methylxanthines.
Figure 3. Survival analysis of time to first change in therapy (days) by index asthma maintenance medication group.
For description of first event, see Table 2. Other included leukotriene receptor antagonists (LTRA) and methylxanthines. ICS: inhaled
corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
6 D. C. GIBBONS ET AL.
Ta
bl
e
3.
As
th
m
a
m
ai
nt
en
an
ce
th
er
ap
ie
s
pr
es
cr
ib
ed
du
rin
g
2-
ye
ar
fo
llo
w
-u
p
by
in
de
x
as
th
m
a
m
ai
nt
en
an
ce
m
ed
ic
at
io
n
gr
ou
p.
To
ta
lp
op
ul
at
io
n
In
de
x
as
th
m
a
m
ai
nt
en
an
ce
m
ed
ic
at
io
n
gr
ou
p
IC
S
IC
S/
LA
BA
O
th
er
b
Pa
tie
nt
s,
n
55
,2
93
46
,2
97
8,
36
7
62
9
Ye
ar
1
Ye
ar
2
Ye
ar
1
Ye
ar
2
Ye
ar
1
Ye
ar
2
Ye
ar
1
Ye
ar
2
IC
S
46
,3
84
(8
4.
7)
24
,3
62
(4
.1
)
46
,2
97
(1
00
)
23
,7
36
(5
1.
3)
40
2
(4
.8
)
49
9
(6
.0
)
13
5
(2
1.
5)
12
7
(2
0.
2)
LA
BA
94
5
(1
.7
)
66
3
(1
.2
)
89
9
(1
.9
)
62
6
(1
.4
)
38
(0
.5
)
30
(0
.4
)
8
(1
.3
)
7
(1
.1
)
IC
S/
LA
BA
11
,8
22
(2
1.
4)
9,
90
0
(1
7.
9)
3,
39
0
(7
.3
)
4,
49
6
(9
.7
)
8,
36
7
(1
00
)
5,
33
4
(6
3.
8)
65
(1
0.
3)
70
(1
1.
1)
LA
M
A
24
5
(0
.4
)
29
3
(0
.5
)
92
(0
.2
)
14
9
(0
.3
)
14
4
(1
.7
)
13
6
(1
.6
)
9
(1
.4
)
8
(1
.3
)
LT
RA
1,
93
9
(3
.5
)
1,
39
7
(2
.5
)
94
3
(2
.0
)
90
1
(1
.9
)
38
6
(4
.6
)
32
0
(3
.8
)
61
0
(9
7)
17
6
(2
8)
Xa
nt
hi
ne
53
(0
.1
)
36
(0
.1
)
11
(<
0.
1)
12
(<
0.
1)
20
(0
.2
)
19
(0
.2
)
22
(3
.5
)
5
(0
.8
)
O
CS
:
An
y
us
e
10
,2
96
(1
8.
6)
7,
09
2
(1
2.
8)
8,
16
5
(1
7.
6)
5,
54
1
(1
2.
0)
1,
99
6
(2
3.
9)
1,
47
4
(1
7.
6)
13
5
(2
1.
5)
77
(1
2.
2)
In
te
rm
itt
en
t
us
e
10
,1
06
(1
8.
3)
6,
90
3
(1
2.
5)
8.
05
2
(1
7.
4)
5,
42
7
(1
1.
7)
1,
92
4
(2
3.
0)
1,
40
3
(1
6.
8)
13
0
(2
0.
7)
73
(1
1.
6)
Ch
ro
ni
c
us
e
19
0
(0
.3
)
18
9
(0
.3
)
11
3
(0
.2
)
11
4
(0
.2
)
72
(0
.9
)
71
(0
.8
)
5
(0
.8
)
4
(0
.6
)
Pr
es
cr
ib
ed
w
ith
ou
t
m
ai
nt
en
an
ce
th
er
ap
y
co
ve
ra
ge
a
1,
91
5
(3
.5
)
2,
18
8
(4
.0
)
1,
49
1
(3
.2
)
1,
74
2
(3
.8
)
38
8
(4
.6
)
41
5
(5
.0
)
36
(5
.7
)
31
(4
.9
)
SA
BD
:
An
y
us
e
48
,4
09
(8
7.
5)
35
,6
64
(6
4.
5)
41
,4
09
(8
9.
4)
30
,0
52
(6
4.
9)
6,
61
5
(7
9.
1)
5,
32
2
(6
3.
6)
38
5
(6
1.
2)
29
0
(4
6.
1)

4
ca
ni
st
er
s
13
,3
74
(2
4.
2)
10
,5
80
(1
9.
1)
11
,1
64
(2
4.
1)
8,
70
6
(1
8.
8)
2,
10
8
(2
5.
2)
1,
78
4
(2
1.
3)
10
2
(1
6.
2)
90
(1
4.
3)
Pr
es
cr
ib
ed
w
ith
ou
t
m
ai
nt
en
an
ce
th
er
ap
y
co
ve
ra
ge
a
11
,9
68
(2
1.
6)
13
,6
30
(2
4.
7)
10
,3
56
(2
2.
4)
11
,7
99
(2
5.
5)
1,
47
9
(1
7.
7)
1,
70
0
(2
0.
3)
13
3
(2
1.
1)
13
1
(2
0.
8)
N
um
be
r
of
pr
es
cr
ip
tio
ns
,m
ea
n
(S
D
):
IC
S
2.
09
(2
.1
4)
1.
13
(1
.9
7)
2.
48
(2
.1
2)
1.
32
(2
.0
8)
0.
09
(0
.4
9)
0.
13
(0
.6
9)
0.
43
(1
.0
5)
0.
47
(1
.2
0)
IC
S/
LA
BA
0.
74
(1
.9
7)
0.
72
(2
.0
8)
0.
26
(1
.2
2)
0.
42
(1
.6
6)
3.
40
(3
.0
)
2.
41
(3
.1
3)
0.
33
(1
.2
7)
0.
35
(1
.3
4)
IC
S:
in
ha
le
d
co
rt
ic
os
te
ro
id
;I
CS
/L
AB
A:
in
ha
le
d
co
rt
ic
os
te
ro
id
/lo
ng
-a
ct
in
g
be
ta
2-
ag
on
is
t.
D
at
a
pr
es
en
te
d
as
n
(%
).
a ‘
Pr
es
cr
ib
ed
w
ith
ou
t
m
ai
nt
en
an
ce
th
er
ap
y’
is
de
fin
ed
,
fo
r
O
CS
an
d
SA
BA
,
as
a
pr
es
cr
ip
tio
n
w
ith
an
is
su
e
da
te
th
at
is
no
t
ac
co
m
pa
ni
ed
by
an
ot
he
r
pr
es
cr
ip
tio
n
fo
r
as
th
m
a
m
ai
nt
en
an
ce
th
er
ap
y
in
th
e
pe
rio
d
be
tw
ee
n
60
da
ys
pr
ec
ed
in
g
an
d
60
da
ys
fo
llo
w
in
g
th
e
is
su
e
da
te
;b
In
cl
ud
ed
le
uk
ot
rie
ne
re
ce
pt
or
an
ta
go
ni
st
s
(L
TR
A)
an
d
m
et
hy
lx
an
th
in
es
.
JOURNAL OF ASTHMA 7
questions relating to asthma control on the same day,
whilst a third of patients had no RCP3Q codes
recorded (not asked any of the questions) (Figure 5).
In year 2, the proportion of patients with a valid
assessment had decreased to 34% with over half of all
patients (57%) having no RCP3Q codes recorded.
Discussion
This retrospective cohort study in non-active users of
asthma maintenance therapy using a ‘new user’ study
design demonstrated a pattern of intermittent use of
maintenance therapies in the 2-year follow-up period.
Many patients who had  3 primary care consulta-
tions for their asthma were often prescribed OCS and
multiple prescriptions ( 4) for SABD over each 1-
year period, and many had  1 exacerbations per
year, indicating a potential tendency for underuse of
maintenance therapies and overuse of SABD by the
population studied. Although time to first treatment
change occurred later in the ICS group, this was likely
driven by inhaler device, as MDIs tend to contain a
greater number of doses per unit in comparison to
DPIs or oral medication, and they will be assumed to
cover patients for a longer period of time. The rela-
tively low proportion of patients having an annual
RCP3Q assessment, may suggest that many primary
care providers utilized a reactive rather than a pro-
active asthma management paradigm; however, eluci-
dating the underlying reasons for this observation are
not possible with the available data.
Whilst a strength of the current study was that it
clearly demonstrated intermittent treatment patterns
in a longitudinal design, these data could not deter-
mine how patients were taking their prescribed main-
tenance therapy – for example, whether they
underused and stockpiled medication – only that there
were periods of prescription absences. As suggested by
other surveys (23–25), patients may have been using
their medication irregularly over an extended period
of time, stopping and starting their treatment when
their symptoms felt better or worse, respectively.
Our study focused on those who were being
‘stepped up’ to asthma maintenance therapy, as these
patients represent a group who have objectively expe-
rienced an acute or sub-acute worsening of symptoms.
This contrast with the approach taken by Gayle et al.
(22) who considered all asthmatics, regardless of
severity, and the vast majority of individuals were at
BTS/SIGN step 0 or step 1 which may have masked
the treatment needs and trajectories of those with
more severe asthma.
The pattern of intermittent maintenance therapy
use observed in this study is consistent with findings
in previous questionnaire-based surveys. In a survey
of 2686 participants with asthma in Australia, of the
1601 participants using ICS or ICS/LABA inhalers,
Figure 4. Proportion of patients prescribed  4 SABD canni-
sters during baseline and follow-up by index asthma mainten-
ance medication group.
Other included leukotriene receptor antagonists (LTRA) and
methylxanthines.
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/
long-acting beta2-agonist
Figure 5. Proportion of patients who had RCP3Q review during follow-up by index asthma maintenance medication group.
Other included leukotriene receptor antagonists (LTRA) and methylxanthines
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist
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43.2% reported using them less frequently than five
days a week, and 30.5% less than weekly (23).
Similarly, in the pan-European REALIZE online sur-
vey, of the respondents who stated that they had a
maintenance therapy inhaler (n¼ 3,481), over half did
not use it every day as prescribed (24). The latest
results of the European Community Respiratory
Health Survey (ECRHS III) showed that whilst there
has been an increase in the use of asthma medication
in the last 20 years, only 34% of subjects with persist-
ent asthma were taking ICS on a regular basis (25).
This irregular use of maintenance therapies has clin-
ical consequences. Approximately a fifth of patients in
our survey had at least one asthma exacerbation
requiring OCS in the first year of follow up, slightly
lower than the incidence reported in the Web-based
surveys (range 29%44% in the last 12months)
(22–24) but these were based on broader asthma pop-
ulations in terms of their treatment and study designs.
As our study solely utilized primary care data – and
was not linked to Hospital Episode Statistics (HES) –
there was the potential for incomplete acquisition of
hospitalizations, exacerbations and emergency depart-
ment visits. In our cohort (who were aged  6 years),
12.6%, 15.3% and 11.3% had  1 exacerbation during
the baseline period, year 1 and year 2 respectively;
accompanying crude rates (per person, per year) were
0.15, 0.19 and 0.14. It should be noted that index date
is included in Year 1, which may mean that the
increased rate of events during this year is attributable
to the acute worsening of symptoms that prompted
the change in asthma therapy. In a recent study utiliz-
ing CPRD-HES data, crude exacerbation rates of
patients deemed to be of a non-atopic, non-obese
phenotype were estimated at 0.20 and 0.39 for
those receiving reliever and maintenance therapy
respectively (26). Another study estimated that 13.7%
of asthma patients of all severities experience  1
exacerbation over the period of a year using the UK
and US databases (8.4% and 12.5% patients with
asthma had  1 exacerbation over the period of a
year, respectively) (17).
Having a history of even one previous exacerbation
is associated with an increased risk of a subsequent
exacerbation (27–30). Two UK database studies in
adults and adolescents with asthma showed that hav-
ing one or more acute courses of OCS in the previous
year was the single best predictor of having two or
more subsequent exacerbations, increasing the odds
by more than three-fold (28,29). Similar data in chil-
dren showed that a past history of asthma attacks was
the best predictor of future attacks (30). An
observational retrospective cohort study in 19 126
Canadian asthmatic patients found that, compared
with non-adherent patients, those who were adherent
to salmeterol/fluticasone had a significantly lower risk
of exacerbations, assessed both by compliance (medi-
cation possession ratio 80%; risk reduction of 52%)
and persistence (prescriptions of the ongoing therapy
being continuously renewed without a gap of more
than 30 days; risk reduction of 58%) (31). These data
and this study reiterate the importance of regular
assessment to ensure patients are on the most appro-
priate therapy for them.
A substantial proportion of patients in this study
were prescribed  4 SABD inhalers/year during the 2-
year follow-up, also a risk factor for severe exacerba-
tions (32). An insufficient prescription of ICS and
over-prescription of SABD were identified as key risk
factors for asthma death in the National Review of
Asthma Deaths in 2014 (33). An audit of 50 UK prac-
tices identified the continuing presence of risk factors
including excessive SABD and insufficient uptake on
ICS prescriptions and failures to issue personal asthma
action plans, highlighting an urgent need for a more
proactive model of care (34). Our findings are com-
patible with those of the Asthma UK survey which
showed that 60% of 10 500 patients still do not receive
basic asthma care comprising three elements: an
annual asthma review, a written asthma action plan
and an inhaler technique check with a healthcare pro-
fessional (35).
This study has some limitations. Patients who were
not continuously registered at a CPRD-contributing
practice would not have had their full prescription
history available. Although the study aimed to investi-
gate patients that were ‘newly’ prescribed maintenance
asthma medications, only 30% had no evidence of
maintenance therapy in their available history.
However, the study design permitted the evaluation of
a large sample of patients that were representative of
asthma patients in the UK in a real-world setting. We
have not attempted to compare RCP3Q score between
years; it is likely that such a comparison would be
subject to a range of biases. For patients who are well
controlled, the assessment may take place at a routine
checkup, whereas RCP3Q may be utilized as a
response to an acute or subacute worsening of symp-
toms in those who have not attained control. Finally,
investigating any associations between prescription
patterns and patient outcomes was beyond the scope
of this analysis. In a future study on treatment pat-
terns, it would be interesting to superimpose patterns
for maintenance, OCS and SABD therapy to
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determine any trends of usage in relation to each
other as well as assessing what association observed
treatment patterns have with scheduled and unsched-
uled HCU.
Conclusion
In conclusion, this study demonstrated that in previ-
ously non-active users of asthma maintenance medica-
tion subsequently commenced on maintenance
therapy, intermittent use was common during the 2-
year follow-up despite the potential need for regular
use as evidenced by patient HCU and SABD usage
patterns. Outside of a patient’s annual review, patient
treatment patterns are driven by self-management and
patients should be trained in the essential skills of
understanding their asthma, how to maintain asthma
control and medication adherence. These findings
highlight the need for regular patient assessment and
education to ensure patients are taking appropriate
medications to maintain asthma control, to monitor
their SABD usage as a potential proxy for poor symp-
tom control, check their inhaler technique, and to
empower patients to be an active partner in managing
their asthma therapy.
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